Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2009
Business Overview: SANUWAVE Health is a medical technology company focused on Pulsed Acoustic Cellular Expression (PACE) technology for wound care, orthopedic, and cardiac applications. On September 25, 2009, the company completed a reverse merger with SANUWAVE, Inc., transitioning from a shell company (formerly Rub Music Enterprises, Inc.) to an operating medical device entity. The company discontinued its veterinary division in June 2009 and its mobile service business in late 2008.
Key Financial Metrics
| Metric (Nine Months Ended Sept 30, 2009) | Value |
|---|---|
| Revenues (Continuing Ops) | $538,818 |
| Gross Profit | $409,402 (76% Margin) |
| Operating Loss | $(6,090,755) |
| Net Loss (Continuing Ops) | $(6,520,796) |
| Net Income (Discontinued Ops) | $3,070,334 |
| Total Net Loss | $(3,450,462) |
| Cash and Cash Equivalents | $3,297,436 |
| Total Debt (Notes Payable, Related Parties) | $8,659,554 |
| Accumulated Deficit | $(35,957,703) |
Material Changes vs. Prior Period
- Revenue Decline: Revenues from continuing operations decreased 38% to $538,818 (from $862,651 in 2008), primarily due to declining sales of the legacy Evotron device in Europe and a strategic shift of resources to the U.S. market.
- Improved Gross Margin: Gross profit margin increased to 76% (from 67% in 2008) driven by a higher mix of sales for the higher-margin dermaPACE device applicator kits.
- Expense Reduction: General and administrative expenses decreased 43% to $3.4 million (from $6.0 million in 2008), largely due to the closure of the European office in April 2009 and reduced headcount.
- Discontinued Operations: The company recorded a significant gain of approximately $2.5 million from the sale of its veterinary division in June 2009, which offset a portion of the operating losses from continuing operations.
- Debt Increase: Notes payable to related parties increased to $8.7 million (from $6.0 million in 2008) due to new financing arrangements to fund operations.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern due to recurring losses and an accumulated deficit of $36 million. The company is economically dependent on future financing to fund ongoing operations.
- Liquidity: As of September 30, 2009, cash reserves of $3.3 million are projected to fund operations through the first quarter of 2010. The company expects to raise additional capital through equity offerings, warrant exercises, or debt financing.
- Outlook: The company anticipates continued operating losses as it funds clinical trials for its lead product candidate, dermaPACE, specifically for diabetic foot ulcers. Research and development expenses are expected to increase.
- Risks: Key risks include the failure to obtain regulatory approval (FDA/CE Mark), inability to secure additional financing, patent litigation, and the volatility of the stock price (trading on OTCBB). The company also faces risks related to single-source suppliers for raw materials.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $3.3 million cash balance to sustain operations beyond Q1 2010 given the high burn rate from clinical trials.
- Debt Obligations: Review the terms of the $8.7 million in related-party notes, specifically the 15% interest rate and conversion features ($2.92/share) which may lead to significant dilution.
- Revenue Sustainability: Assess the transition from legacy European device sales to the commercialization of dermaPACE in the U.S. market.
- Regulatory Milestones: Monitor the progress of the dermaPACE clinical trial for diabetic foot ulcers and the timeline for FDA approval.
- Reverse Merger Impact: Confirm the post-merger capital structure and the extent of dilution resulting from the issuance of shares and warrants to SANUWAVE stockholders.